Arrowhead Pharmaceuticals (ARWR) Stock Forecast & Price Target

Arrowhead Pharma is supported by a rare combination of clinical validation, platform breadth, and nearer-term commercial optionality, with ARO-MAPT showing up to 73% mean CSF total tau reduction at Day 105 and no serious treatment-emergent adverse events in the interim healthy-volunteer dataset. The company also strengthened its revenue case in severe hypertriglyceridemia, as SHASTA-3 and SHASTA-4 delivered median triglyceride reductions of 79% and 81% at Month 12, plus a prespecified pooled 78% reduction in adjudicated acute pancreatitis events and a one-year NNT of 24. Beyond these headline results, the preserved Priority Review Voucher, potential 2027 launch, and at least four additional CNS candidates by end-2027 suggest multiple shots on goal and meaningful platform value beyond any single asset.

Arrowhead Pharma is viewed negatively because its clinical profile shows meaningful safety issues, with any TEAE in 90% of ARO-MAPT patients in Part 1a and 83% in Part 1b versus 53% on placebo, while common adverse events like headache and injection site reactions remained elevated and key hematology and NfL data were not disclosed. Its continued cash burn raises the likelihood of future debt or equity financing that could dilute shareholders or come with restrictive covenants, and funding may be hard to secure on acceptable terms. The company also faces substantial execution risk from uncertain clinical endpoints, regulatory outcomes, patent protection challenges, and intense competition from better-resourced rivals across RNAi and gene-therapy approaches.